{
  "id": 20962882,
  "title": "Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027",
  "url": "https://urgent.news/2026/11/20/pfizers-launched-and-acquired-drugs-grew-32-in-q3-and-3-other-reasons-20962882",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T22:35:02.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/pfizers-launched-and-acquired-drugs-grew-32-q3-and-3-other-reasons-buy-stock-2027"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsPfizer is a well-respected drugmaker facing typical industry headwinds.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "2 Reasons to Buy SpaceX (SPCX) Stock -- and 1 Reason to Wait",
        "url": "https://urgent.news/2026/11/19/2-reasons-to-buy-spacex-spcx-stock-and-1-reason-to-wait",
        "published": "2026-11-19T21:44:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}